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We aimed to analyze markers of immune activation, inﬂammation, and oxidative stress in 92 asymptomatic HIV-infected patients
according to the adequate (AR, >500 cells/mm3) or inadequate (IR, <500 cells/mm3) CD4+ T recovery and the presence or absence
of antiretroviral treatment (cART). In relation to those newly diagnosed, they were divided into two groups, cART-naïve IR (nIR)
and cART-naïve AR (nAR). Among those diagnosed more than ﬁve years ago, the following division was made: the cART-naïve
long-term nonprogressors (LTNP); patient under cART and AR (tAR); and patients under cART and IR (tIR). We investigated
the expression of soluble receptor for advanced glycation end products (sRAGE), high-mobility group-box protein −1
(HMGB1), soluble CD14 (sCD14), IL-8, IL-10, 8-isoprostane, vitamins, and DNA damage. We observed higher levels of sRAGE
in tAR as compared to nIR, nAR, LTNP, and more sCD14 than in nIR and nAR. As for IL-10 levels, we found
nIR> nAR> LTNP> tAR> tIR. Higher levels of 8-isoprostane were observed in nIR. LTNP presented a higher retinol dosage
than tAR and less genotoxic damage induced by oxidative stress than the other groups. We suggest that the therapy, despite
being related to lesser immune activation and inﬂammation, alters the vitamin proﬁle and consequently increases the oxidative
stress of patients. In addition, the lowest genotoxic index for LTNP indicates that both VL and cART could be responsible
for the increased DNA damage. More studies are needed to understand the inﬂuence of cART on persistent immune
activation and inﬂammation.
1. Introduction
HIV infects many cell types, especially CD4+ T lymphocytes,
and its activation provokes cytopathic eﬀects through the
production of new viral copies [1]. This results into a
progressive deterioration of the cellular immune system
and a severe immunodepression, which makes the individual
more susceptible to opportunistic diseases [2].
Until the 1990s, the most common causes of death were
associated with infections caused by Pneumocystis jirovecii,
Toxoplasma gondii, cytomegalovirus, and avian-intracellu-
lare complex mycobacteria, among others [3]. However, with
the advent of combined antiretroviral therapy (cART), the
survival of HIV-infected subjects increased signiﬁcantly, as
a consequence of viral replication control and immunological
and clinical parameter improvement [4], as well as lower
rates of virus transmission [2, 5].
Despite therapeutic eﬃcacy, some latent-infected cells
keep the provirus integrated into their DNA, but without
expressing viral proteins, known as “reservoirs” [6]. This
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condition remains until the cell is stimulated and activated,
thus delaying the immune system’s response against the virus
and hammering the action of antiretroviral drugs [1, 6],
which should be used throughout the patient’s life.
It is also known that the existence of viral reservoirs
contributes to intense immune activation [7], leading to a
chronic inﬂammatory status and triggering a series of
non-AIDS-associated comorbidities, such as cardiovascular,
hepatic, bone, renal, and metabolic and neoplastic diseases
[8–11]. In fact, these diseases are currently the leading causes
of death among people living with HIV/AIDS (PLWHA) [2].
In addition to the persistent inﬂammation caused by HIV
itself, the infection is also related to increased oxidative stress,
one of the adverse eﬀects that may be induced by therapy
[12]. It is known that PLWHA, especially those under
treatment, present a large imbalance between oxidants and
antioxidants [13–15]. For example, in the presence of cART,
decreased levels of vitamins, their precursors, and some
antioxidants [16, 17] as well as high concentrations of lipid
peroxidation products, such as 8-isoprostane, are observed.
In addition, mitochondrial toxicity and DNA damage are
also observed in this population [18, 19].
Another mechanism that participates in immune
activation and inﬂammation is the homeostatic imbalance
of the gut-associated lymphoid tissue (GALT), which pro-
motes the rupture of the epithelial barrier and microbial
translocation to the circulation, measured by lipopolysaccha-
ride (LPS) and soluble CD14 (sCD14), among other markers
[7, 20]. This immune activation, which can be triggered via
Toll-like receptors (TLRs), activates the transcription factor
NFκb, leading to the transcription of cytokines and other
inﬂammatory products, such as IL-6, IL-8, and HMGB1
(high-mobility group-box protein −1), and to the increase
of the expression of RAGE (receptor for advanced glyca-
tion end products) and other receptors on the cell
membrane [20–22]. Studies show increased inﬂammatory
mediators in PLWHA [23], even in those under cART,
which is responsible for only a partial decrease in the
inﬂammatory status. Thus, these constant stimuli lead to
immunosenescence and to the early aging process of
PLWHA [8, 10, 12].
Considering the need of clarifying the mechanisms
responsible for intense cellular immune activation, persistent
inﬂammation, and oxidative stress, the aim of the present
study was to investigate some of these markers in diﬀerent
groups of asymptomatic PLWHA, according to the use of
cART and its diﬀerent CD4+ T lymphocyte counts.
2. Material and Methods
2.1. Study Design. This cross-sectional study was conducted
between 2012 and 2015 at the Specialist Outpatient Service
for Infectious Diseases “Domingos Alves Meira,” Botucatu
Medical School Complex (FMB)-UNESP, in São Paulo state,
Brazil. This service assists approximately 600 HIV-infected
people from Botucatu and its surrounding area. For this
study, 250 consecutive patients were interviewed, but only
94 of them were included according to the exclusion criteria.
They were divided into ﬁve groups, according to Figure 1.
The intention to study groups without treatment was to
investigate the inﬂuence of therapy on oxidative status and
immune activation of PLWHA in order to open new discus-
sions on the beneﬁts versus harms in the early indication of
cART, as these days in several countries.
2.2. Inclusion and Exclusion Criteria. PLWHA inclusion
criteria were age between 20 and 50 years, no previous cART
administration, or patients undergoing treatment for more
than ﬁve years and presenting undetectable viral load (copies
of HIV-1 RNA≤50 copies/mm3) in such period. For them,
adherence to cART was conﬁrmed by the patient himself
and by the records of medication collection at the services’
pharmacy. All subjects included signed an informed consent
form. Considering that many habits and comorbidities could
Figure 1: Flowchart for patients’ inclusion and division into study groups, according to the presence or not of combined antiretroviral
therapy (cART), CD4+ T cells count (cells/mm3), and time of HIV diagnosis.
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be confounding variables and would interfere in our analysis
of oxidative stress [22], patients carrying any of the following
conditions were excluded: use of vitamin supplements,
cancer history (current or previous), anorexia, morbid
obesity, diabetes mellitus, cardiovascular, genetic or autoim-
mune diseases, organ transplants, use of illicit drugs and
alcohol, pregnancy at any stage or breastfeeding, AIDS
symptoms (those with opportunistic infections), or coin-
fections, such as tuberculosis or chronic viral hepatitis.
For the following criteria, exclusion occurred when patients
concomitantly reported two or more of them: regular
performance of intense physical exercise; use of antibiotics,
anxiolytics, or antidepressants; and active smoking. People
with only one of these conditions were included because
the statistical analysis was adjusted for these variables.
2.3. Sociodemographic and Clinical Data. These data were
collected by interviews and from the patients’ medical
records, taking into account the date of blood collection for
this study.
2.4. Analyses of Laboratory Tests. Twelve milliliters of blood
was collected into an EDTA-containing tube from each
patient included in the study. The material was maintained
in a cooled and dark environment for 2-3 hours. After that,
60μl of total blood was separated for the comet assay proce-
dure and the remaining sample was centrifuged at 1500 rpm
for 10 minutes. Six plasma aliquots per individual were
stored at −80°C until the tests were performed.
2.4.1. Evaluation of Immune Activation
(i) Measurement of plasma HMGB1: a sandwich
enzyme-linked immunosorbent assay (ELISA) was
performed, using 100μl of a diluted sample (1 : 10)
and following themanufacturer’s speciﬁcations from
a commercial kit (MyBioSource, item MBS2707497).
Plasma HMGB1 concentration was determined
by spectrophotometry, at 450 nm. Results were
expressed as pg/ml using the optical density (OD)
of the curves and samples for this calculation.
(ii) Measurement of soluble receptor for advanced
glycation end products (sRAGE) and sCD14: Using
100μl of pure samples, the sandwich ELISA protocol
was developed according to the manufacturer’s
instructions (R&D Systems, item DRG00 to sRAGE
and DC-140 to sCD14). Readings were performed
immediately by a spectrophotometer at the wave-
length of 450nm. OD of the samples and curve
was calculated and expressed in pg/ml.
(iii) Measurement of IL-8, and IL-10: cytokine
measurement was performed by ﬂow cytometry
(FACSCalibur E34297502374) using the CBA (cyto-
metric bead array) kit of inﬂammatory cytokines,
according to the manufacturer’s instruction manual
(BD-Becton, Dickinson and Company, item551811).
The ﬂuorescence intensity, from the cytometer,
showed the amount of cytokines present in the
sample. With the samples, standards containing
known concentrations of each cytokine were
analyzed together for the drawing of the curve,
reading, and establishment of the respective
detection limits. Results were obtained in pg/ml by
the software FCAP array™ (BD-Becton, Dickinson
and Company).
2.4.2. Evaluation of Oxidative Stress
(i) Evaluation of lipid peroxidation by analysis of 8
isoprostane: The plasma aliquots destined for this
assay were stored at −80°C in the presence of
0.005% BHT (butylated hydroxytoluene). ELISA
was performed according to the manufacturer’s
instructions (Cayman, item 516351) using 50μl of
plasma and read at 412nm. Optical densities were
calculated in pg/ml.
(ii) Analysis of DNA damage in white blood cells by the
Comet Assay: It was developed according to Sasaki
et al. [24] using 30μl of whole blood set on a
blade with agarose. After lysis solution treatment,
triplicates of the blades were subjected to three
diﬀerent conditions in electrophoresis: basal condi-
tion (BAS), formamidopyrimidine DNA glycosylase
(FPG), or endonuclease III (END) addition for
detection of oxidative damage in purine and pyrim-
idine bases, respectively (Biocompare, CA, USA).
The slides were stained by Sybr Gold (Invitrogen,
USA). Using an immunoﬂuorescence microscope
connected to an image analysis system (comet assay
IV, Perceptive Instruments, Suﬀolk, Haverhill, UK), a
total of 50 randomly selected nucleoids were
counted for each slide. Results were expressed as
“tail intensity” (ti), which is the percentage of
migrated DNA and “tail moment” (tm), relative
values from the fraction of migrated DNA multi-
plied by the length of the tail.
(iii) Analysis of antioxidants by concentration of fat-
soluble vitamins: They were measured from 100μl
of plasma by HPLC (Waters 2996), by a C30 column
(150× 4.6mm, 3μm), and according to Ferreira and
Matsubara [25]. The wavelength used was 455nm
for carotenoids (lutein, cryptoxanthin, lycopene
and, β-carotene), 325 nm for retinol, and 290nm
for α-tocopherol. The values of the standard solution
of the substances were ﬁxed by their molar extinc-
tion coeﬃcients expressed in μmol/ml.
2.5. Analysis of Results. We used a generalized linear model
with Poisson or negative binomial distribution for count
variables and gamma distribution for asymmetric variables
or binomial negative one-way ANOVA followed by Tukey-
Kramer post hoc tests for those symmetric data. Pearson
correlations were adopted to analyze continuous variables.
After ﬁtting the model, confounding variables (age, sex, and
tobacco use, practice of intense physical activity, and use of
anxiolytics and/or antidepressants) were added in order to
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evaluate their inﬂuence on the comparisons made. Signiﬁ-
cant diﬀerences were considered when p values were less than
or equal to 0.05. All these procedures were performed with
help from professionals at the institution’s research support
oﬃce using SAS for Windows, version 9.2.
This study was approved by the Research Ethics
Committees of the Botucatu Medical School, registration
number 4101-2011.
3. Results
Most of the participants were males (61.9%) aged 37± 8
years, white (88.1%), heterosexual (70.6%), and single
(66.3%). Approximately 24% were active smokers; almost
20% practiced intense physical activity, and 4.0% used anxi-
olytics or antidepressants (Table 1). The groups were homo-
geneous as regards the above-mentioned factors (p > 0 05).
The mean time of HIV infection, from the HIV diagnosis,
was 7± 2 years. The lowest nadir of CD4+ T cells was
observed in tIR, followed by tAR, and then by nIR. The
means of CD4+ T, CD8+ T cells, VL, time of therapy use,
and cART schemes are shown in Table 1.
Among the markers studied, sRAGE was higher in
tAR (1798.33± 437.21 pg/ml) than in the naïve groups
(1332.44± 505.94 in nIR, p = 0 040; 1358.67± 758.87 in
nAR, p = 0 050; 1089.32± 600.62 pg/ml in LTNP, p = 0 009).
tAR (11078.54± 9975.14 pg/ml) also showed the highest
levels of sCD14; though these, diﬀerences were statistically
signiﬁcant only in comparison to nIR (6751.66± 1693.36,
p = 0 016) and nAR (6903.02± 1819.33 pg/ml, p = 0 046).
HMGB1 protein levels were not diﬀerent between groups.
These data are shown in Figure 2.
As for cytokines, IL-8 production showed no diﬀer-
ences among groups. Conversely, IL-10 expression was
lower in the cART groups, and higher in nIR and nAR.
The means of IL-10 were 0.63± 0.93 pg/ml in nIR, 0.24±
1.15 in nAR, 0.07± 0.19 in LTNP, 0.02± 0.03 in tAR,
and 0.01± 0.00 pg/ml in tIR. Diﬀerences between naïve
groups and those under cART reached statistical signiﬁcance
as shown in Figure 3.
Some oxidative stress parameters were also studied,
including 8-isoprostane, vitamins, and DNA damage
analysis. 8-isoprostane was higher in nIR, in comparison to
the other groups. As shown in Figure 4, the means and stan-
dard deviations of 8-isoprostane were 64334.88± 12669.83
for nIR; 31855.79± 28720.15 for nAR; 30367.25± 15091.16
for LTNP (p = 0 005); 32936.75± 18513.95 for tAR and
40018.33± 25888.53 for tIR (p < 0 050).
As for the carotenoids, the dosage of lutein was lower
in tIR (5.99± 3.12μmol/ml) than in the other groups (in
nIR, 11.47± 7.12, p = 0 006; in nAR, 12.98± 6.66, p = 0 022;
in LTNP, 16.08± 9.00, p = 0 050; and in tAR, 11.76±
6.09μmol/ml, p = 0 020). There was also a diﬀerence in cryp-
toxanthin concentration, with nAR (16.45± 6.39μmol/ml,
p = 0 003) and LTNP (18.73± 8.00μmol/ml, p = 0 041)
having higher levels than the cART groups (tAR, 7.44± 3.88
and tIR, 7.33± 2.04μmol/ml) and than nIR (10.08±
5.55μmol/ml).
No diﬀerences were observed among the groups for
β-carotene and lycopene dosages. Diﬀerences in mean
retinol concentration were observed only between LTNP
and tAR (0.45± 010 and 0.30± 0.10μmol/ml, respectively,
p = 0 035), while α-tocopherol dosages were comparable
among the groups included in the study (Figure 5).
Table 1: Epidemiological and clinical characterization of 92 HIV-infected individuals studied.
Variables nIR(1) nAR(2) LTNP(3) tAR(4) tIR(5) p value
Age (ME± SD; years) 34.0± 8.3 36.9± 9.4 35.8 ± 6.2 39.1± 7.1 40.0± 7.1 0.057
Males (n/%) 14/70.0% 13/65.0% 5/41.6% 10/50.0% 13/65.0% 0.288
Heterosexual (n/%) 12/60.0% 14/70.0% 10/83.3% 15/75.0% 14/70.0% 0.600
Single (n/%) 14/70.0% 13/65.0% 7/58.3% 11/55.0% 15/75.0% 0.695
Smokers (n/%) 7/35.0% 3/15.0% 4/33.3% 3/15.0% 4/20.0% 0.531
Physical activity (n/%) 2/10.0% 5/25.0% 2/16.6% 6/30.0% 3/15.0% 0.304
Antidepressants (n/%) 2/10.0% 1/5.0% 0/0.0% 0/0.0% 1/5.0% 0.859
CD4+ T (ME± SD; cells) 341.6± 121.9∗(2–4) 699.3± 142.8 862.1± 360.1 833.7± 212.5 343.3± 140.0∗(2–4) <0.001
CD8+ T (ME± SD; cells) 1120.2± 903.0 1431.1± 739.9∗(4, 5) 1261.3± 672.6 899.7± 292.6 880.1± 579.9 <0.010
Nadir CD4 (ME± SD; cells) 316.5± 143.7∗(2) 568.7± 122.9 526.5± 244.5 294.4± 162.2∗(1, 2) 98.1± 92.4∗all <0.010
VL (ME± SD; RNA copies) 527± 1394∗(2, 3) 67± 58 36± 79 Undetectable Undetectable <0.001
HIV diagnosis (ME± SD; years) 2.1± 1.0∗(4, 5) 1.9± 0.8∗(4, 5) 7.6± 2.2 14.5± 3.9 10.6± 4.3 <0.010
Time of cART (ME± SD; years) — — — 9.0± 4.4 8.3± 3.5 ne
PI-based scheme (n/%) — — — 13/32.5% 10/25.0% 0.587
NNRTI-based scheme (n/%) — — — 7/17.5% 8/20.0% 0.500
Rescue therapy (n/%) — — — 0/0.0% 2/5.0% 0.269
cART: combined antiretroviral therapy; ne: not evaluated; ME: mean; SD: standard deviation; n: number of subjects; VL-HIV plasma viral load (expressed in
copies × 103/ml); CD4+ T and CD8+ T cell counts (expressed in number of cells/mm3); nIR, 20 cART-naïve with CD4+ T < 500 cells/mm3; nAR, 20 naïve with
CD4+ T > 500; LTNP, 12 naïve with CD4+ T > 500 and infection for more than ﬁve years; tAR, 20 cART patients with undetectable VL and CD4+ T > 500 for
more than ﬁve years; tIR, 20 cART patients with undetectable VL and CD4+ T < 500 for more than 5 years; IP: protease inhibitor; NNRTI: nonnucleoside
reverse transcriptase inhibitor. Statistical tests: negative binomial, ANOVA, Poisson, and Chi-square. ∗Statistical diﬀerences between speciﬁed groups (1–5).
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When comparing the DNA damage of the studied
groups, LTNP (0.07± 0.02, tail moment) showed minor
damages than the other groups, considering the slides treated
with FPG (nIR, 0.18± 0.06, p = 0 033; nAR, 0.12± 0.08,
p = 0 050; tAR, 0.15± 0.02, p = 0 041; and tIR, 0.16± 0.08,
p = 0 035). No diﬀerences were observed among the groups
for untreated (BAS) blades or those treated with END. These
data are shown in Figures 6 and 7.
By Pearson analysis, positive correlations were found
between CV and two markers, HMGB1 (p = 0 0211) and
IL-10 (p = 0 003). Negative correlations occurred between
CD4+ T cells and two variables, IL-8 (p = 0 027) and HMGB1
(p = 0 0240).
In addition, we veriﬁed the correlation between the
markers of immune activation and some parameters that
could also be related to its increase, such as CD4+ T nadir,
time of HIV diagnosis, and time of therapy, and no
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Figure 2: Plasma levels of soluble receptor for advanced glycation end products (sRAGE), high-mobility group-box 1 protein (HMGB1),
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Figure 4: Plasma levels of 8-isoprostane of 92 people living with
HIV/AIDS, according to the ﬁve composed groups. This marker is
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associations were found, considering all subjects in the
study together.
4. Discussion
The recent introduction of cART correlates with both
longer life expectancy of PLWHA and the development
of non-AIDS comorbidities, which occur earlier in HIV-
infected subjects than in the general population [10–12].
The “early aging” of these subjects is caused by constant
immune activation and chronic inﬂammation which leads
to the exhaustion of the immune system and the imbalance
of cytokines and other immunological and physiological
components [8, 10, 12].
Several receptors and proteins promote cellular activa-
tion and consequently the activation of the signaling cascade
that give rise to the inﬂammatory components. RAGE is a
pattern recognition receptor (PRR) which activates the cell
due to its interaction with its ligands, for example, AGEs
and HMGB1 [25]. Conversely, its soluble form, sRAGE
[26], acts as a suppressor of activation, since it arrests the
RAGE ligands, preventing the interaction between them
and the subsequent cellular signaling [22].
We detected higher sRAGE levels in the cART group
with higher CD4+ T cell counts as compared to the non-
cART groups. The possible explanation for this observation
is more than a few. First, in the blood circulation of these
individuals, there could be a greater accumulation of ligands
for this receptor [22], such as sCD14, which was increased in
the tAR group in the present study. Second, the levels of
sRAGE could mirror the possible partial decrease of inﬂam-
mation presented by cART patients [23]. This last argument
could be justiﬁed, even, by the smaller dosages of IL-8
found in the same group of patients, although diﬀerences
did not reach statistical signiﬁcance. High concentrations
of sRAGE have been related to the fewer occurrences of
atherosclerosis in PLWHA [27], hypercholesterolemia [28],
and arterial hypertension [29] in individuals not infected by
HIV, suggesting that its dosage could be a useful tool in the
diagnosis of cardiovascular diseases in PLWHA [27].
HMGB1 in its extracellular form is secreted actively
following cellular stimulus, or passively by necrotic and
apoptotic cells, and performs similar functions to those of
proinﬂammatory cytokines [30]. Due to its binding to RAGE
and other PRRs present in CD4+ T cells, HMGB1 may even
induce HIV reactivation [31]. We did not ﬁnd any diﬀerence
in the levels of this protein among the ﬁve groups. However,
HMGB1 correlated negatively with CD4+ T counts and
positively with VL, validating the longitudinal study by
Trøseid et al. [32], who showed a signiﬁcant HMGB1
reduction after introduction of cART.
Youn et al. [21] found that monocyte stimulation with
the association of LPS and HMGB1 led to higher TNF-α
production compared to LPS alone. Taken together, the
ﬁndings by Trøseid et al. [32] and Youn et al. [21] may
indicate that higher levels of HMGB1 might contribute to
poorer clinical outcomes in HIV-infected individuals, as
there would probably be more cellular activation, reactiva-
tion of the latent virus, and increased production of
inﬂammatory cytokines in these individuals. In addition,
elevated HMGB1 plasma levels are related to other chronic
inﬂammatory conditions in non-HIV-infected individuals
including diabetes mellitus and cancer [25, 33]. Thus, there
is a need to investigate the inﬂuence of cART on the decrease
of this marker in order to delay the development of HIV
infection and the appearance of non-AIDS comorbidities.
Among microbial translocation markers, sCD14 is
related to monocyte activation and its concentration is higher
in PLWHA compared to uninfected individuals. It is also
associated with the characteristic comorbidities of aging in
this population [34, 35]. Here, the group of individuals
receiving cART and presenting high CD4+ T cell counts
showed higher levels of sCD14 as compared to naïve groups
and to those with recent infection, which was also demon-
strated by Sandler et al. [36]. This fact could be related to
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the time of infection and therapy because, despite viral sup-
pression at plasma levels, GALT is one of the viral
reservoirs that can sustain HIV replication [37] in a T cell-
deﬁcient environment, whereas cART is not able to
completely restore Th17 cells in GALT [38]. However,
in the present study, the increase in sCD14 did not
occur in cART patients presenting CD4+ T cells below
500 cells/mm3, as it would be expected, since these individ-
uals would probably have fewer T lymphocytes and an even
scarcer immune response in GALT, which would further
compromise the balance of this mucosa.
Diﬀerently from our results, other authors have shown a
relationship between greater microbial/polymicrobial trans-
location in immunological nonresponders and associated it
with intestinal ﬂora imbalance [39]. The importance of
studying the sCD14 marker in PLWHA is also justiﬁed by
the observations that there is an association between sCD14
and increased risk for cardiovascular disease [40] and that
sCD14 is a predictor of all mortality causes in HIV patients,
even in those with undetectable VL [36].
In HIV infection, there is imbalance not only of the Th17
proﬁle but also of Th1, Th2, and regulatory T cells (Treg).
Additionally, large numbers of inﬂammatory cytokines are
found in HIV-positive patients, which may inﬂuence the
development to AIDS and the onset of non-AIDS comorbidi-
ties [41]. IL-10 is a regulator of the inﬂammatory immune
response [42]. In the present study, this cytokine showed
diﬀerent concentrations in the diﬀerent groups. The highest
levels were found in naïve patients presenting a recent infec-
tion, intermediate levels in naïve patients who had been diag-
nosed more than ﬁve years before, and the lowest in
individuals under cART. These results agree with those by
Brockman et al. [42], which showed a reduction in both IL-
10 plasma levels and its mRNA expression in cART subjects
presenting adequate viral suppression as compared to naïve
individuals, with the exception of elite controls, who presented
similar values to those of uninfected individuals, suggesting
that viral replication may be the main determinant of cytokine
concentrations. Likewise, in the present study, a positive
correlation was also found between VL and IL-10 levels.
As reported by Haissman et al. [43], IL-8 showed a
negative correlation with CD4+ T cells, which evidenced
higher levels of inﬂammatory cytokines in individuals with
CD4+ T cell counts below 200 cells/mm3. Thus, the monitor-
ing of inﬂammatory cytokines could be included in the
follow-up of patients in order to evaluate the evolution of
HIV infection.
It is known that the constant presence of these inﬂamma-
tory components and the residual replication of HIV induce
oxidative stress in PLWHA, which occurs when there is over-
production of ROS and RNS or a reduction in antioxidant
capacity. Such oxidative stress is potentiated by the toxic
eﬀects of cART [19]. For example, PIs are known to deregu-
late ubiquitin-proteasome proteins (UPS) that will contribute
to endoplasmic reticulum stress, as well as to lipid accumula-
tion, the development of insulin resistance and diabetes
⁎
Ta
il 
in
te
ns
ity
Ta
il 
m
om
en
t
40.00
30.00
20.00
10.00
0.00
BAS END FPG
0.00
0.05
0.10
0.15
0.20
BAS END FPG
tIR
tAR
LTNP
nAR
nIR
tIR
tAR
LTNP
nAR
nIR
Figure 6: Leukocyte DNA damage of the 92 people living with HIV/AIDS, according to the ﬁve study groups, in three conditions—basal
(BAS), that is, blades without enzymes treatment, or blades with enzymatic treatment (endonuclease III enzyme [END] and
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Figure 7: Leukocyte DNA damage representation of ﬁve selected nucleoids of patients living with HIV/AIDS, according to the ﬁve study
groups, whose slides were treated with the formanodipirimidina-DNA glycosylase (FPG) enzyme. By the analysis of the Comet assay, the
immunoﬂuorescence microscopy shows that LTNP presents less damage than the other groups.
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mellitus, and an increased risk for atherosclerosis [44].
In addition, PIs activate intracellular apoptosis pathways
and increase the prooxidant status of the intracellular
environment [44]. On the other hand, NRTIs inhibit DNA
polymerase, decreasing mitochondrial DNA and presenting
membrane loss, lower respiratory rates, and oxidative phos-
phorylation, which consequently induces greater production
of ROS and oxidative stress [45].
We found that 8-isoprostane, a marker of lipid peroxida-
tion, was higher in naïve individuals with CD4+ T cells below
500 cells/mm3 than in the other groups. This can be
explained by the association between high oxidative stress
in patients who have high VL and a poor immune system.
Thus, in our study, cART does not appear to have increased
levels of this marker, diﬀerently from other ﬁndings by
Redhage et al. [18] and Hulgan et al. [14] in which cART
individuals, even those with a controlled viral replication,
had increased levels of 8-isoprostane. These authors also
pointed out that PLWHA under cART without NNRTI in
their composition had higher rates of 8-isoprostane as
compared to those who used it or to naïve individuals. High
levels of this marker are also found in several non-AIDS
comorbidities, including atherosclerosis [46], which high-
lights the need for further studies aimed at reducing this
parameter in PLWHA.
Carotenoids have the ability to arrest free radicals, and
many are precursors of retinol or vitamin A. In the
immune system, retinol stimulates phagocytosis, T cell
proliferation, activation of cell-mediated cytotoxicity, and
antibody production and contributes to intestinal mucosal
homeostasis [47, 48]. However, studies have shown
deﬁciency of β-carotene and retinol in the HIV-infected
population [49, 50] as compared to uninfected individuals,
which was also evident in subjects under cART [49]. As
for the carotenoids and the dosages of β-carotene and
lycopene, the groups showed no diﬀerence between each
other. However, the lutein level was lower in the cART
group presenting low CD4+ T cell counts, suggesting that
both the use of cART and immunodeﬁciency could
inﬂuence lutein levels. Cryptoxanthin also appears to be
inﬂuenced by cART and the immune response. Indeed,
its concentration increased in naïve patients with high
levels of CD4+ T cells compared to naïve individuals with
an inadequate immune response or the cART groups. Retinol
was also higher in naïve patients with high CD4+ T cell
counts, proving the importance of the natural mechanisms
of HIV infection control that these individuals show.
α-Tocopherol is a lipid-soluble antioxidant that acts by
blocking the lipid peroxidation of polyunsaturated fatty acids
from membranes and lipoproteins. It also blocks the
activation of NFκB and the consequent production of
proinﬂammatory cytokines and has physiological potential
in the reduction of atherosclerosis [51]. There was no
diﬀerence in the α-tocopherol levels between the groups
studied here, but for other authors, there was a decrease in
vitamin E [52] in individuals with low CD4+ T cell count.
Such diﬀerences may be related to diﬀerent study designs
and characteristics of the population. However, we did not
evaluate the cART schemes used by the participants or their
vitamin E percent deﬁciency. In a Brazilian study, deﬁciency
of this vitamin was found in almost 20% of PLWHA, which
occurred more frequently in cART patients who did not use
NNRTI in their composition [17]. Following the antioxidant
deﬁciency in this population and their importance in
reducing oxidative stress, their monitoring should be rou-
tinely introduced and micronutrient supplements should be
recommended when necessary.
In the long term, oxidative stress leads to genotoxic
eﬀects which can either be repaired or lead to mutagenicity
[53]. When comparing DNA damage in our groups, there
was less oxidative damage in naïve patients with infection
for more than ﬁve years and CD4+ T cell counts higher than
500 cells/mm3. One possible explanation is that as these
individuals have good control of viral replication and
CD4+ T counts without the cART administration, they
might be able to activate more eﬃcient DNA repair mecha-
nisms [54]. After all, it is known that both HIV VL and
antiretrovirals may contribute to genotoxic increase in
these patients [14, 55, 56], as observed in the other groups
studied here.
There are few human studies on the frequency of DNA
damage and its consequences for HIV infection and the
appearance of other comorbidities, and there are few
in vivo studies about the interference of cART in this context.
Considering that genomic instability may contribute to the
development of neoplasias and that such comorbidities are
common in the HIV-infected population, it would be
interesting to have more studies evaluating the inﬂuence
of chronic use of cART as well as the persistent immune
activation and inﬂammation in PLWHA in these geno-
toxic alterations.
This study present some limitations, such as its cross-
sectional design, reduced number of individuals in LTNP
group, and the lack of food surveys or anthropometric
measures. However, other factors were deeply considered,
such as strict exclusion criteria, group homogeneity regard-
ing sociodemographic variables, and data analysis adjusted
for gender, age, tobacco use, intense physical activity, and
use of anxiolytics and/or antidepressants.
5. Conclusions
We found that patients with cART, viral suppression for over
ﬁve years, and high CD4+ T cell count (> 500 cells/mm3)
have higher levels of sRAGE and sCD14 and this group along
with that under cART and low CD4+ T cell count showed
lower levels of IL-10 and vitamins compared to naïve
subjects. This result suggests that cART may not restore cell
functions in GALT, which would compromise local homeo-
stasis, induce microbial translocation, and consequently lead
to the increase of some soluble ligands (e.g., sRAGE) in an
attempt to minimize the activation, via RAGE or TLR. In
addition, despite the incontestable beneﬁts of cART, these
drugs can inﬂuence the antioxidant defense of the body,
considerably reducing some vitamins which could compro-
mise the oxidative balance and contribute to the persistent
inﬂammation in PLWHA.
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We also showed that high plasma concentrations of
8-isoprostane occurred in naïve individuals with CD4+ T
cells below 500 cells/mm3, evidencing the participation
of HIV viral replication in increasing oxidative stress.
Regarding DNA damage, the group of naïve patients with
CD4+ T cell count higher than 500 cells/mm3 and diagnosed
more than ﬁve years ago (LTNP) showed a lower genotoxic
index than all the other groups, indicating that both VL
and cART may be responsible for the DNA damage increase,
a process that could perhaps be alleviated by speciﬁc intrinsic
factors of the organism, such as more eﬃcient repair mecha-
nisms and protective genes in certain individuals.
Further studies are needed to understand the persistent
mechanisms of activation and inﬂammation, inﬂuenced or
not by cART, in order to guarantee greater longevity and
better quality of life for PLWHA.
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